MHC Class Ib Polypeptides for Myelin-Specific Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) and MOG antibody disease, such as MS and MOG antibody positive neuromyelitis optica, face challenges with insufficient immunomodulation or severe side effects, and there is a lack of effective therapeutics for MOGAD, with existing strategies being complex, expensive, or risky.
Innovation Solution
The use of recombinant polypeptides comprising peptide antigens and domains of non-classical MHC class Ib molecules, particularly HLA-G, to induce antigen-specific tolerance and suppress immune responses, including the design of covalently linked molecules with β2-microglobulin and alternative antigen-binding domains to enhance flexibility and versatility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunomodulatory therapies are used to suppress immune responses in MS and MOGAD, then disease activity can be controlled, but severe side effects occur including progressive multifocal leukoencephalopathy
Solution Approach 1:
The invention uses antigen-specific tolerogenic dendritic cells that are segmented and differentiated to present specific myelin antigens (MOG, MBP, PLP, MAG) to T cells, inducing antigen-specific tolerance rather than global immunosuppression. This segmented approach targets only the pathological immune responses while preserving protective immunity.
Solution Approach 2:
The patent employs dendritic cells as intermediary cells that bridge the antigen and T cells. These tolerogenic dendritic cells express specific costimulatory molecules and cytokines that mediate the induction of regulatory T cells, acting as a safe intermediary to suppress pathological immune responses without the severe side effects of conventional immunomodulators.
2Reliability
If large amounts of antigens are administered to induce antigen-specific tolerance, then tolerance may be induced, but severe side effects occur and clinical success is not achieved
Solution Approach 1:
Dendritic cells serve as biological carriers that present antigens in a tolerogenic context. Instead of administering large amounts of free antigen, the invention uses dendritic cells as intermediaries to deliver antigens (MOG, MBP, PLP, MAG) in a controlled manner that induces tolerance without the harmful effects of high-dose antigen administration.
Solution Approach 2:
The invention changes the parameters of antigen delivery by using dendritic cells with specific phenotypic and functional characteristics. The dendritic cells are differentiated to express specific costimulatory molecules (CD80, CD86, CD40) and cytokines (IL-10, TGF-β) that alter the immune response parameters from activation to tolerance induction.
3Reliability
If adoptive transfer of antigen-specific regulatory T cells or antigen-loaded tolerogenic dendritic cells is used, then antigen-specific tolerance can be induced, but the therapy becomes extremely complex and expensive
Solution Approach 1:
The patent develops a universal platform using dendritic cells that can be loaded with different myelin antigens (MOG, MBP, PLP, MAG) to treat different forms of demyelinating diseases. This multi-functional approach allows a single therapeutic strategy to address multiple disease manifestations, reducing overall complexity compared to developing separate therapies for each antigen-specific condition.
Solution Approach 2:
The invention performs preliminary differentiation and loading of dendritic cells with antigens ex vivo before administration. This preliminary action allows for quality control and standardization of the tolerogenic dendritic cells, making the therapy more reproducible and potentially less complex than attempting to induce tolerance in vivo after administration of raw antigens.
4Reliability
If common biologics are administered to achieve immunomodulation, then immune responses can be suppressed, but the drugs cannot cross the blood-brain barrier to have anti-inflammatory effect in situ
Solution Approach 1:
The patent uses dendritic cells as living carriers that can cross the blood-brain barrier and deliver antigens directly to the central nervous system. These cellular intermediaries navigate the blood-brain barrier that small molecule biologics cannot cross, enabling in situ immunomodulation within the CNS.
Solution Approach 2:
The dendritic cells possess inherent migratory capabilities and can self-navigate to lymphoid tissues and potentially cross the blood-brain barrier without requiring external delivery systems. This self-service property allows the therapeutic cells to reach their target sites autonomously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant polypeptides effectively suppress immune responses against myelin proteins, reduce autoantibody formation, and improve safety by minimizing severe side effects, offering a promising treatment for MS and MOG antibody diseases.
Implementation Method 1
human MHC class Ib molecules such as HLA-G possess the ability to induce antigen-specific tolerance towards presented peptide antigens
Data Source
AI summary
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.